Short-term Results of the RAPID <u>Ra</u>ndomized Trial of the Legflow <u>P</u>aclitaxel-Eluting Balloon With Supera Stenting vs Supera Stenting Alone for the Treatment of <u>I</u>nterme<u>d</u>iate and Long Superficial Femoral Artery Lesions

Abstract

The short-term results from the multicenter RAPID randomized controlled trial indicate that the Legflow PEB is safe and feasible for the treatment of intermediate to long SFA lesions. In this trial, at least 70% of the patients suffered an occlusion. The PEB group had higher rates of primary patency and freedom from CD-TLR, although there were no statistically significant differences vs controls.